ClinicalTrials.gg
CompletedNCT03302624SURIAUpdated Nov 17, 2026

Follow-up of Long-term Renal Function After Acute Kidney Injury in ICU

An observational study in Acute Kidney Injuries, Quality of Life and Chronic Kidney Disease, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
287
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 154 studies in Acute Kidney Injury with a site in France — 31 open to participants now, 35 under way, 4 of them phase 3. Acute Kidney Injury · France.

Enrollment
30th of 76
287 · median 190
Started
2017
with 6 others
Observational
76 of 154
13 open now
Registered
48th of 154
by date
Lead sponsor
4 of 154
University Hospital, Clermont-Ferrand

Among the 154 studies in Acute Kidney Injury with a site in France, this one is the 30th largest by enrollment of the 76 observational ones that give a count, is one of 7 that started in 2017, is one of 76 observational ones, and was the 48th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

31 of the 154 studies in Acute Kidney Injury with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Acute Kidney Injury with a site in France, or all of them as a file.
02

Study summary

Acute kidney injury (AKI) involves poor prognosis in ICU patients. The renal prognosis at long term is unknown.

The study will determine chronic kidney injury incidence and quality of life, five years after AK during ICU stay.

Read the detailed description

Prospective study. All patients who participated ELVIS study (clinical trials: 00875069) can be enrolled in SURIA.

Patients are contacted by telephone. Investigator delivery objective and honest information. If patients accepts the study, answers will be collected.

Collected data are: creatinine serum, two surveys (quality of life and activities of daily living), date of onset of renal replacement therapy.

03

Conditions studied

  • Acute Kidney Injuries
  • Quality of Life
  • Chronic Kidney Disease
  • Renal Replacement Therapy

Keywords

  • acute kidney injury
  • quality of life
  • Renal replacement therapy
  • Intensive care unit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

ICU patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ICU Patients included in ELVIS study, AKI requiring renal replacement therapy Length of ICU stay ≥ 48h

Exclusion criteria

Exclusion Criteria:

Pregnant or nursing woman's job

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
287 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients who were included in ELVIS study
06

What researchers measure

Primary outcomes

  1. incidence of chronic kidney disease

    incidence of chronic kidney disease in patients who had an acute kidney injury during their ICU stay and requiring an renal replacement therapy

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

Secondary outcomes

  1. severity of CKD according to the International Classification of Chronic Kidney Disease

    Kidney function will be measured by creatinine serum or chronic dialysis or kidney transplantation

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

  2. impact of the renal replacement therapy on long-term renal function

    Intermittent or continuous renal replacement therapy. Data collected in the database from ELVIS study. Kidney function will be measured by creatinine serum or chronic dialysis

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

  3. quality of life

    Quality of life will be assessed with the Q5D score

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

  4. Activities of daily living

    Activities of daily living will be assessed with the Katz adjustment scales

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

  5. Mortality

    Mortality

    Time frame: 5 years after the first acute kidney injury requiring renal replacement therapy

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Soum E, Timsit JF, Ruckly S, Gruson D, Canet E, Klouche K, Argaud L, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Darmon M, Bohe J, Schwebel C, Bouadma L, Dupuis C, Souweine B, Lautrette A. Predictive factors for severe long-term chronic kidney disease after acute kidney injury requiring renal replacement therapy in critically ill patients: an ancillary study of the ELVIS randomized controlled trial. Crit Care. 2022 Nov 29;26(1):367. doi: 10.1186/s13054-022-04233-4. PubMed 36447221 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2018, 12 months.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 12 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2017 → Sep 2018 and completion Dec 2017 → Dec 2018.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 5, 2017
StartActual
Sep 1, 2017
Primary completionActual
Sep 1, 2018was Dec 2017
CompletionActual
Dec 1, 2018was Dec 2017
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Dec 1, 2017→Sep 1, 2018 (actual)
Nov 17, 2026
Study completion
Dec 31, 2017→Dec 1, 2018 (actual)
Nov 17, 2026
Enrollment
506 (estimated)→287 (actual)
Nov 17, 2026
Publications
Results publication added: Soum E, Timsit JF, Ruckly S, Gruson D, Canet E, Klouche K, Argaud L, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Darmon M, Bohe J, Schwebel C, Bouadma L,… PubMed 36447221 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Soum E, Timsit JF, Ruckly S, Gruson D, Canet E, Klouche K, Argaud L, Garrouste-Orgeas M, Mariat C, Vincent F, Cayot S, Darmon M, Bohe J, Schwebel C, Bouadma L,… PubMed 36447221 ↗
    Primary completion Dec 1, 2017→Sep 1, 2018 (now actual)
    Study completion Dec 31, 2017→Dec 1, 2018 (now actual)
    Enrollment 506 (estimated)→287 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03302624
Responsible party
Sponsor
First posted
Oct 5, 2017
Start date
Sep 1, 2017
Primary completion
Sep 1, 2018
Completion
Dec 1, 2018
Last update
Nov 17, 2026

Study contacts

Alexandre LAUTRETTE
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion